Neal A. Chatterjee et al. JCHF 2014;2:

Slides:

Advertisements

Similar presentations

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: The HVAD Left Ventricular Assist Device: Risk Factors.

Advertisements

From: Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.

Table 2 Laboratory and echocardiographic values before LVAD implantation in the two groups. From: Reversibility of fixed pulmonary hypertension in left.

Circ Cardiovasc Interv

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.

Noriko Kikuchi et al. JACEP 2016;2:

Endothelial Dysfunction in Patients With Lone AF and AF Patients With Comorbidities Compared With That in Controls Comparisons are shown among control.

Carolyn Y. Ho et al. JCHF 2015;3:

David S. Frankel et al. JACEP 2015;1:

David F. Katz et al. JACEP 2016;j.jacep

Stavros Stavrakis et al. JACEP 2015;1:1-13

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Wayne L. Miller et al. JCHF 2013;1:

Giuseppe Boriani et al. JACEP 2016;2:

Mohit K. Turagam et al. JACEP 2017;3:

Mintu P. Turakhia et al. JACEP 2016;2:

Hemodynamic Assessment of Patients With and Without Heart Failure Symptoms Supported by a Continuous-Flow Left Ventricular Assist Device Rabea Asleh,

G. Michael Felker et al. JCHF 2014;2:

Svend A. Mortensen et al. JCHF 2014;2:

Yoshitaka Kimura et al. JACEP 2016;2:

Kenshi Hayashi et al. JACEP 2016;2:

Should Patients 60 Years and Older Undergo Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices? Jeremiah G. Allen, MD, Arman.

David F. Katz et al. JACEP 2017;3:20-28

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Gordon R. Reeves et al. JCHF 2017;j.jchf

Peter E. Carson et al. JCHF 2015;3:

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Jerry D. Estep et al. JCHF 2013;1:

Mintu P. Turakhia et al. JACEP 2016;2:

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Colonization With Multiresistant Bacteria: Impact on Ventricular Assist Device Patients Maria Papathanasiou, MD, Julia Pohl, MD, Rolf Alexander Jánosi,

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Associations between β-blocker dosage group, predischarge heart rate group, and the primary composite outcome of death or cardiovascular rehospitalisation.

John Rickard et al. JCHF 2013;1:

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Jacqueline Baras Shreibati et al. JCHF 2017;j.jchf

Jeffrey B. Geske et al. JCHF 2018;j.jchf

Early Outcomes With Marginal Donor Hearts Compared With Left Ventricular Assist Device Support in Patients With Advanced Heart Failure Erin M. Schumer,

Maria Rosa Costanzo et al. JCHF 2016;4:95-105

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Jordan B. King et al. JCHF 2016;4:

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Stavros V. Konstantinides et al. JACC 2017;69:

Natasha A. Loghmanpour et al. JCHF 2016;4:

Rick A. Nishimura et al. JACC 2014;63:e57-e185

Connie W. Tsao et al. JCHF 2016;4:

Jeffrey J. Teuteberg et al. JCHF 2015;3:

Kaplan-Meier survival estimates for major cardiovascular events.

Christian Madelaire et al. JCHF 2018;6:

Satoru Kishi et al. JCHF 2014;2:

The impact of concomitant pulmonary hypertension on early and late outcomes following surgery for mitral stenosis Bo Yang, MD, PhD, Christina DeBenedictus,

Medically Refractory Pulmonary Hypertension: Treatment With Nonpulsatile Left Ventricular Assist Devices Christian D. Etz, MD, Henryk A. Welp, MD, Tony.

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Zeenat Safdar et al. JCHF 2014;2:

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Maxime Berthelot-Richer et al. JIMG 2016;9:

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Orly Vardeny et al. JCHF 2016;4:

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

Time to first event analysis revealed a significant difference in estimated event-free (death or hospitalisation) survival between patients with left ventricular.

Maria R. Costanzo et al. JCHF 2016;4:

Patient selection process in the present study.

Survival of subjects listed for heart transplantation with different spirometric ventilatory patterns. Survival of subjects listed for heart transplantation.

Survival of subjects listed for heart transplantation with and without spirometry. Survival of subjects listed for heart transplantation with and without.

Daniele Muser et al. JACEP 2017;j.jacep

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Presentation transcript:

Neal A. Chatterjee et al. JCHF 2014;2:230-237 PH Subtype and Clinical Outcome Kaplan-Meier estimates of the probability of survival free of (A) the composite clinical outcome (death, heart transplantation, left ventricular assist device [LVAD] placement) or (B) all-cause mortality assessed at 2 years for patients without pulmonary hypertension (PH), PH with transpulmonary gradient (TPG) <12 mm Hg, and PH, TPG ≥12 mm Hg. Comparison testing of survival from clinical endpoints is shown for patients with PH, TPG ≥12 mm Hg versus those without PH and those with PH, TPG <12 mm Hg (log-rank p). There was no significant difference between patients with PH, TPG <12 mm Hg and patients without PH with respect to freedom from the composite outcome (log-rank p = 0.11) or all-cause mortality (log-rank p = 0.33). Neal A. Chatterjee et al. JCHF 2014;2:230-237 American College of Cardiology Foundation